Welcome to Greg Rowland’s Alzheimer’s Research Report.

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

Due to the significant amount of research and writing to bring each report to life, this is a subscription-only publication. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

Please consider subscribing so this publication is sustainable. Your subscription also directly supports my Alzheimer’s treatment expenses. Thank you!

Subscribe now

SUMMARY

This is a free report with no paywall. The information is valuable to everyone impacted by Alzheimer’s disease. After reading this report, please consider subscribing so you have access to all Greg Rowland’s Alzheimer’s Research Reports.

FULL REPORT

There are many exciting advances in Alzheimer’s disease research and treatments in 2026.

On the research side, early blood tests for diagnosis are a major focus.​ Additionally, many researchers are studying lifestyle and immune-based interventions. Several universities are working to better understand Alzheimer’s as a disease. We still do not know the cause of Alzheimer’s.

​In this report, I am focusing on treatment advances. Let’s begin by reviewing lecanemab and donanema​b.

​A retrospective study of ​patients in the United States treated ​with lecanemab for an average of 17 months reported that 75.9% remained in the same disease stage and 6.6% improved​. There were no significant adverse effects beyond those reported in clinical trials. ​Since early Alzheimer’s disease often progresses slowly, and the study had no untreated comparison group, these figures describe how treated patients fared, not how much stability ​lecanemab caused.

As a patient removed from lecanemab after 18 infusions due to frequent side effects (chills, shivers, and muscle pain), I am a tad skeptical about the overall benefit of the drug.

​Lecanamab ​has recently received approval for self-injection using an autoinjector that ​the patient or a caregiver can use for subcutaneous injection. ​This new treatment method is called LEQEMBI IQLIK (pronounced “i-click​”). This is a huge advancement for patient convenience.

Clinicians may consider stopping ​donanemab after amyloid PET confirms a reduction to minimal plaque levels. In the pivotal program, 47% of treated participants met the trial’s PET completion criteria by 12 months and 69% by 18 months. Reaching a PET threshold is not the same as a cure or proof of clinical stability, and amyloid can reaccumulate​. ​Lilly is studying whether infrequent maintenance dosing could keep amyloid low​.1

​Both lecanemab and donanemab are not cures; ​they do not restore lost memory, and ​they may not produce a noticeable day-to-day difference for every patient.​ I noticed a progression of the disease during the eight months I received lecanemab infusions.

​Lecanemab and donanemab can modestly reduce the average rate of decline in carefully selected people with early, amyloid-confirmed Alzheimer’s disease. Whether that potential benefit is worth the MRI surveillance, infusion or injection burden, ARIA and hemorrhage risk, uncertainty, and cost is ​a decision each patient must make.

Trontnemab

I have previously reported (here and here) that Trontinemab​ is designed to improve delivery of an anti-amyloid antibody across the blood-brain barrier using a transferring-receptor brain shuttle. ​Early trial data is promising. In my layperson opinion, I believe crossing the blood-brain barrier is the key for a successful anti-amyloid antibody​ therapy.

The Phase 3 TRONTIER studies in early Alzheimer’s disease patients are underway, enrolling roughly 1,600 participants across two identical trials, with primary completion estimated in 2028.2

Tau-Directed Therapies

Many new Alzheimer's drugs target tau because tau tangles track closer to actual memory loss and brain decline than amyloid plaques do. While current anti-amyloid medications are designed to clear amyloid plaques, they offer only modest benefits. Scientists hope tau-focused therapies will better stop nerve cell destruction.

Posdinemab: an investigational anti-tau monoclonal antibody that was developed by Johnson & Johnson. However, development was discontinued after clinical trials showed it failed to slow cognitive decline. 3

Bepranemab: an investigational, humanized monoclonal antibody designed to target the mid-region of the tau protein, developed as a potential disease-modifying treatment for Alzheimer's disease. While a major Phase 2 trial missed its broad primary endpoint, imaging data showed it significantly slowed cortical tau accumulation. 4

Etalanetug (E2814): an investigational anti-microtubule-binding region (MTBR) tau monoclonal antibody. Developed by Eisai and University College London, it is designed to block the spread of toxic tau protein tangles in the brain. 5

Diranersen (BIIB080): an investigational antisense oligonucleotide therapy developed by Ionis Pharmaceuticals and licensed by Biogen to target microtubule-associated protein tau (MAPT) mRNA, aiming to reduce tau protein production in early Alzheimer's disease. I have previously reported on Diranersen.

Presymptomatic Treatment and Risk-Reduction Trials

AHEAD 3-45: a global clinical trial testing lecanemab to see if it can slow cognitive decline and brain changes during the preclinical stage of Alzheimer's disease in adults aged 55 to 80 who have no outward memory symptoms.6

TRAILBLAZER-ALZ 3: an ongoing Phase 3 clinical trial evaluating whether the donanemab can prevent or delay the onset of Alzheimer's symptoms. 7

Tau NextGen: a worldwide Phase II/III clinical research study led by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University. It tests combination therapies using lecanemab and the anti-tau antibody etalanetug (E2814) to treat genetic Alzheimer's disease.8

If you know of a drug I missed, please let me know, and I will update this report.

Before I go, I want to share a link to Greg Rowland’s Alzheimer’s Journey published yesterday. If you can contribute, it would mean the world to me. If not, please share the post on your social media networks. Thanks!

Subscribe now

Welcome to Greg Rowland’s Alzheimer’s Research Report.

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

Due to the significant amount of research and writing to bring each report to life, this is a subscription-only publication. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

I believe the value of a full month of my research reports matches (or exceeds!) the value of a single coffee and muffin. Another comparison, if you prefer a nice craft cocktail, is the Zig Zag Cafe in Seattle, where a cocktail will set you back $17. A full month of my research reports is only $10. And, I promise zero hangovers.

Please consider subscribing so this publication is sustainable. Thank you!

Subscribe now

SUMMARY

Apitherapy is an alternate therapy that relies on using honeybee products, most​ importantly bee venom, to treat many human diseases​. These natural products have been used​ for health purposes since ancient times. ​More recently, apitherapy has been studied as a potential treatment for Alzheimer’s disease (AD).

Read more

Welcome to Greg Rowland’s Alzheimer’s Research Report.

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

Due to the significant amount of research and writing to bring each report to life, this is a subscription-only publication. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

I believe the value of a full month of my research reports matches (or exceeds!) the value of a single coffee and muffin. Another comparison, if you prefer a nice craft cocktail, is the Zig Zag Cafe in Seattle, where a cocktail will set you back $17. A full month of my research reports is only $10. And, I promise zero hangovers.

Please consider subscribing so this publication is sustainable. Thank you!

Subscribe now

SUMMARY

A recent study ​led by Flinders University in partnership with researchers from the University of New South Wales and Macquarie University found that tau is essential for turning new experiences into lasting memories by helping organize the brain’s memory-storing cells.​ The mouse study also revealed how abnormal tau may contribute to Alzheimer’s by disrupting both the​ formation of new memories and the recall of existing ones.

Subscribe now

Read more

Welcome to Greg Rowland’s Alzheimer’s Research Report.

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

Due to the significant amount of research and writing to bring each report to life, this is a subscription-only publication. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

I believe the value of a full month of my research reports matches (or exceeds!) the value of a single coffee and muffin. Another comparison, if you prefer a nice craft cocktail, is the Zig Zag Cafe in Seattle, where a cocktail will set you back $17. A full month of my research reports is only $10. And, I promise zero hangovers.

Please consider subscribing so this publication is sustainable. Thank you!

Subscribe now

SUMMARY

Deep cervical lymphovenous anastomosis (DCLVA) is an exploratory microsurgical procedure developed in China to treat Alzheimer's disease by connecting neck lymphatic vessels to veins to accelerate brain waste clearance. Following rapid adoption across hundreds of hospitals with thousands of procedures performed, China’s National Health Commission restricted its use due to a lack of rigorous randomized trial data.

Is this procedure a viable Alzheimer’s treatment?

Read more

Welcome to Greg Rowland’s Alzheimer’s Research Report.

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

Due to the significant amount of research and writing to bring each report to life, this is a subscription-only publication. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

I believe the value of a full month of my research reports matches (or exceeds!) the value of a single coffee and muffin. Please consider subscribing so this publication is sustainable. Thank you!

Subscribe now

SUMMARY

After nine years of work, researchers have developed a highly reproducible three-dimensional human brain tissue model capable of replicating complex neurodegenerative processes in Alzheimer’s disease. The engineered tissue model includes key Alzheimer’s-relevant genes and proteins, forms functional synaptic networks, and exhibits active microglial surveillance.

Subscribe now

Read more

Welcome to Greg Rowland’s Alzheimer’s Research Report.

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

Due to the significant amount of research and writing to bring each report to life, this is a subscription-only publication. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

I believe the value of a full month of my research reports matches (or exceeds!) the value of a single coffee and muffin. Please consider subscribing so this publication is sustainable. Thank you!

Subscribe now

SUMMARY

A University of Minnesota research team has identified a type of plaque that represents a new potential therapeutic target for Alzheimer’s disease.

Subscribe now

Read more

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

Due to the significant amount of research and writing to bring each report to life, this is a subscription-only publication. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

I believe the value of a full month of my research reports matches (or exceeds!) the value of a single coffee and muffin. Please consider subscribing so this publication is sustainable. Thank you!

Subscribe now

SUMMARY

My report today covers recent news from Biogen, AstraZeneca, and Bristol Myers Squibb. I also discuss Alzheimer’s advocacy work Bill Ritter of WABC-TV is leading.

Finally, I write about the importance of brain health at an early age.

Subscribe now

Read more

Welcome to Greg’s Alzheimer’s Research Report.

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

Due to the time required for research and writing, Greg’s Alzheimer’s Research Report is a subscription-only publication. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

Subscribe now

SUMMARY

QuantumCell, a Danish tech-enabled biotech company, has acquired global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856. The deal is valued at approximately 2.2 billion US dollars.

Read more

Welcome to the new format of Greg’s Alzheimer’s Research Report.

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

On average, I spend three hours producing each report. This rigorous process involves scouring scientific journals for critical topics, tracking clinical trial updates, and analyzing extensive background data to bring you accurate, actionable information.

Effective July 14, 2026, our format will change. The brief report summaries will remain free to all readers, while access to the complete, in-depth reports will transition to a paid subscription model.

This subscription directly supports the time and research required to sustain this platform. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

Subscribe now

SUMMARY

ProMIS Neurosciences has developed PMN310, an experimental monoclonal antibody treatment for early Alzheimer’s disease. Six-month interim safety and biomarker results from the Phase 1 trial show no ARIA-E (brain swelling) and 4.4% total ARIA (brain bleeding). The ARIA cases were all mild and asymptomatic.

Read more

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

On average, I spend three hours producing each report. This rigorous process involves scouring scientific journals for critical topics, tracking clinical trial updates, and analyzing extensive background data to bring you accurate, actionable information.

Effective July 14, 2026, our format will change. The brief report summaries will remain free to all readers, while access to the complete, in-depth reports will transition to a paid subscription model.

This subscription directly supports the time and research required to sustain this platform. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

Subscribe now

SUMMARY

An Italian clinic recently conducted a one-year real-world study of Alzheimer’s patients receiving lecanemab or donanemab. The study was a small group of patients. The structured infusion process and follow-up procedures make this a extremely credible study. The purpose of the study was not to compare lecanemab with donanemab. Rather, the study focused on the effectiveness and safety of amyloid targeting therapy.

Read more

Welcome to the new format of Greg’s Alzheimer’s Research Report.

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

On average, I spend three hours producing each report. This rigorous process involves scouring scientific journals for critical topics, tracking clinical trial updates, and analyzing extensive background data to bring you accurate, actionable information.

Effective July 14, 2026, our format will change. The brief report summaries will remain free to all readers, while access to the complete, in-depth reports will transition to a paid subscription model.

This subscription directly supports the time and research required to sustain this platform. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

Subscribe now

SUMMARY:

Interest in NeuroEPO (also called NeuralCIM) is surging among Alzheimer’s patients and their loved ones in the United States. In this report, I provide the reasons why an American pharmaceutical company is not licensing NeuroEPO or manufacturing a similar drug. Most importantly, this report gives you all the information needed to safely travel to Cuba to obtain this very promising drug.

Please consider subscribing to read this report. All proceeds support my Alzheimer’s treatment.

Thank you.

Read more

Welcome to the new format of Greg’s Alzheimer’s Research Report.

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

On average, I spend three hours producing each report. This rigorous process involves scouring scientific journals for critical topics, tracking clinical trial updates, and analyzing extensive background data to bring you accurate, actionable information.

Effective July 14, 2026, our format will change. The brief report summaries will remain free to all readers, while access to the complete, in-depth reports will transition to a paid subscription model.

This subscription directly supports the time and research required to sustain this platform. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

SUMMARY

Lecanemab is a controversial Alzheimer’s (AD) drug designed to slow the progression of the disease. Many experts question if Lecanemab’s high cost, safety concerns, and modest benefit are worth AD patients taking the infused drug.

Subscribe now

In this report, I present Lecanemab financial data obtained from investor reports. Eisai (the codeveloper along with Biogen) of Lecanemab is bullish on the future of their AD therapies. Please subscribe to read this report and support my Alzheimer’s treatment..

Read more

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

On average, I spend three hours producing each report. This rigorous process involves scouring scientific journals for critical topics, tracking clinical trial updates, and analyzing extensive background data to bring you accurate, actionable information.

Effective July 14, 2026, our format will change. The brief report summaries will remain free to all readers, while access to the complete, in-depth reports will transition to a paid subscription model.

This subscription directly supports the time and research required to sustain this platform. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

Summary:

While Alzheimer’s disease (AD) was historically viewed strictly through the lens of amyloid plaques and neurofibrillary tangles, decades of research have positioned chronic neuroinflammation as the third core pathological feature of AD.

Read more

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

On average, I spend three hours producing each report. This rigorous process involves scouring scientific journals for critical topics, tracking clinical trial updates, and analyzing extensive background data to bring you accurate, actionable information.

Effective July 14, 2026, our format will change. The brief report summaries will remain free to all readers, while access to the complete, in-depth reports will transition to a paid subscription model.

This subscription directly supports the time and research required to sustain this platform. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

SUMMARY

Blood-based biomarkers of Alzheimer disease pathology have advanced rapidly recently, and are now increasingly used in research, clinical trials, and clinical practice. Blood-based biomarkers promise to improve accurate diagnosis of Alzheimer disease, with the potential for much greater reach than cerebrospinal fluid or PET tests. Yet, there are current clinical limitations to blood-based biomarkers.

Read more

Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.

On average, I spend three hours producing each report. This rigorous process involves scouring scientific journals for critical topics, tracking clinical trial updates, and analyzing extensive background data to bring you accurate, actionable information.

Effective July 14, 2026, our format will change. The brief report summaries will remain free to all readers, while access to the complete, in-depth reports will transition to a paid subscription model.

This subscription directly supports the time and research required to sustain this platform. We offer three ways to stay informed:

• Monthly Subscription: $10 per month

• Annual Subscription: $100 per year (Save $20 annually)

• Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)

SUMMARY

Yesterday, Eisai and Biogen issued a joint statement with results of the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study. This study shows the results of actual patient use of lecanemab.

Subscribe now

Read more